IP Library Granted Patent US 9,757,375
Granted Patent B2
US 9,757,375 · App. 14/729,642 · Granted Sep 12, 2017

Compounds that inhibit human DNA ligases and methods of treating cancer

Inventors: Alan E. Tomkinson (Albuquerque, NM); Helen Xi Chen (Austin, TX); Barbara Dziegielewska (Charlottesville, VA); Alexander D. Mackerell (Baltimore, MD); Shijun Zhong (Catonsville, MD); Gerald M. Wilson (Middle River, MD)
Assignee: University of Maryland, Baltimore
A61K31/505A61K31/165A61K31/166A61K31/175A61K31/255A61K31/341A61K31/397A61K31/404A61K31/41A61K31/4184A61K31/423A61K31/428A61K31/4245A61K31/433A61K31/436A61K31/4439A61K31/495A61K31/553A61K45/06A61N5/10C07D209/30C07D235/28C07D257/04C07D263/58C07D267/18C07D271/12C07D277/74C07D285/14C07D307/68C07D401/12C07D407/12C40B30/02G01N21/64G06F19/16G06F19/706
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,757,375
App. No.
14/729,642
Granted
Sep 12, 2017
Kind
B2
Abstract

Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.

Claims (8)

1. A method of ameliorating neuroblastoma exhibiting an altered DNA damage response in a patient in need comprising administering to said patient an effective amount of an anti-cancer compound according to the chemical structure as set forth below:

in combination with a second cancer treatment comprising a DNA damaging agent.

2. The method according to claim 1 wherein said DNA damaging agent is ionizing radiation, a PARP inhibitor or a DNA alkylating agent.

3. The method according to claim 2 wherein said DNA damaging agent is a PARP inhibitor.

4. The method according to claim 3 wherein said PARP inhibitor is 3-aminobenzamide.

5. The method of claim 1 , wherein said DNA damaging agent is administered at the same time as administering said compound.

6. The method of claim 1 , wherein said DNA damaging agent is administered prior to administering said at least one compound.

7. The method of claim 1 , wherein said DNA damaging agent is administered after administering said at least one compound.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 14, 2016
From: UNIVERSITY OF MARYLAND BALTIMORE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039152/0953 →
Continuity (5)
Division 13864916 · Apr 17, 2013
Division 12576410 · Oct 9, 2009
Continuation In Part PCTUS2008059931 · Apr 10, 2008
Provisional Application 60911000 · Apr 10, 2007
Related Publication 20150313898A1 · Nov 5, 2015